Generate Biomedicines (GENB) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zenas BioPharma is the larger company by market cap ($1.72 billion vs $1.72 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | ZBIO |
|---|---|---|
| Share price | $13.41 | $26.42 |
| Market cap | $1.72B | $1.72B |
| 1-day change | -1.18% | -6.25% |
| YTD return | — | -22.39% |
| 1-year return | — | +35.16% |
| EPS (TTM) | $-2.44 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $44.60 |
| 52-week low | $11.00 | $13.50 |
| Distance from 52-week high | -40.85% | -40.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +101.34% | +81.23% |
| Average volume | 1.04M | 735.12K |
| Shares outstanding | 128.35M | 65.18M |
| Employees | 312 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
GENB vs ZBIO FAQ
Which is bigger, Generate Biomedicines or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.72B compared with $1.72B for Generate Biomedicines (GENB).
Are Generate Biomedicines and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.